- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03693092
LAmbre™ Left Atrial Appendage Closure System Follow-Up Study
LAmbre™ Left Atrial Appendage Closure System Post-Market 2-5 Years Follow-Up Study
연구 개요
상태
정황
상세 설명
All subjects who completed 1-year follow-up of the LAmbreTM LAA system registration trial will be conducted 2 years, 3 years, 4 years and 5 years follow-up by the telephone call.
During the follow-up, the investigator or his/her designee will use a standardized form to record the occurrence of the subject's safety events and validity endpoint by telephone,and complete the safety and efficacy summary report. The endpoints of the study included compound events, MACCE events, stroke, haemorrhage and other events.
연구 유형
등록 (예상)
연락처 및 위치
연구 장소
-
-
-
Chengdu, 중국
- West China Hospital, Sichuan University
-
연락하다:
- Jian Jiang
-
-
Beijing
-
Beijing, Beijing, 중국
- Beijing Chaoyang Hospital, Capital Medical University
-
Beijing, Beijing, 중국
- Fuwai Hospital Chinese Academy of Medical Science
-
연락하다:
- Yan Yao
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국
- The 2nd Affiliated Hospital of Harbin Medical University
-
연락하다:
- bo Yu
-
-
Hubei
-
Wuhan, Hubei, 중국
- Wuhan Asia Heart Hospital
-
연락하다:
- Xi Su
-
Wuhan, Hubei, 중국
- People's Hospital of Wuhan University
-
연락하다:
- Congxin Huang
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국
- Jiangsu Province Hospital
-
연락하다:
- Minglong Chen
-
-
Liaoning
-
Shenyang, Liaoning, 중국
- The General Hospital Of Shenyang Military Region
-
연락하다:
- Zulu Wang
-
-
Shandong
-
Dalian, Shandong, 중국
- The First Affiliated Hospital of Dalian Medical University
-
연락하다:
- Yanzong Yang
-
-
Shanghai
-
Shanghai, Shanghai, 중국
- Shanghai Tenth People's Hospital
-
연락하다:
- Yawei Xu
-
Shanghai, Shanghai, 중국
- Xinhua Hospital Affiliated Shanghai Jiaotong University School of Medicine
-
연락하다:
- Yigang Li
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients who participated in the LAmbreTM Safety and Efficacy Study and completed the 1-year follow-up.
The inclusion criteria of LAmbreTM Safety and Efficacy Study:
- Age>=18, CHADS2 score>=1
- Patients cannot be treated long-term with Warfarin
- Eligible for clopidogrel and aspirin
- Provide written informed consent and agree to comply with the required follow-ups
Exclusion Criteria:
- Exclusion criteria: Patients who did not participate in the LAmbreTM Safety and Efficacy Study or did not complete 1-year follow-up LAmbreTM Safety and Efficacy Study.
The exclusion criteria of LAmbreTM Safety and Efficacy Study:
- Need to take Warfarin
- Presence of rheumatic, degenerative or congenital valvular heart diseases
- Early stage or paroxysmal atrial fibrillation
- Symptomatic patients with carotid artery disease (such as carotid stenosis>=50%)
- Heart failure NYHA grade IV
- Recent 30 days stroke or TIA
- Presence of active sepsis or endocarditis
- Cardiac tumours or other malignancy with estimated life expectancy <2 years
- Abnormal blood test; renal dysfunction
- LAA removed or heart implant patients
- Patients have planned electrophysiological ablation or cardioversion 30 days post implantation of the LAmbre system
- Patients have a history of mechanical prosthesis operation
- Patients who are pregnant, or desire to be pregnant during the during the study
- Participation in other trials
- A known allergy to nitinol
- Patients will not be able to complete the trial
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
The incidence of compound event
기간: 5 years after the surgery
|
The compound event including death, systemic embolization, complications related to the device and requiring treatment (cardiac embolism, embolization, stroke, hemorrhage, death).
|
5 years after the surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
The incidence of MACCE events
기간: 2,3,4,5 years postoperative follow-up.
|
The MACCE events including death (All cause death, All-cause death includes cardiac death, non-cardiac death and unexplained death), stroke, cardiac tamponade, and renal failure.
|
2,3,4,5 years postoperative follow-up.
|
Ischemic stroke rate
기간: 2,3,4,5 years postoperative follow-up
|
Ischemic stroke is a neurological deficit caused by transient ischemic attack, cerebral thrombosis or cerebral embolism.
|
2,3,4,5 years postoperative follow-up
|
The rate of stroke
기간: 2,3,4,5 years postoperative follow-up
|
Stroke is deviated into ischemic, hemorrhagic or undetermined stroke, and transient ischemic attacks (TIA).
|
2,3,4,5 years postoperative follow-up
|
The event of bleeding
기간: 2,3,4,5 years postoperative follow-up
|
Intracranial or alimentary canal, or any bleeding that requires transfusion of 2 units of red blood cell suspension.
|
2,3,4,5 years postoperative follow-up
|
Cardiac events
기간: 2,3,4,5 years postoperative follow-up
|
Non-fatal myocardial infarction, arrhythmia, cardiac tamponade, cardiogenic shock, endocarditis.
|
2,3,4,5 years postoperative follow-up
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Congxin Huang, People's Hospital of Wuhan University
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심방세동에 대한 임상 시험
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음과도한 Supraventricular Ectopies 또는 Short Atrial Runs(ESVEA)
-
University of Pennsylvania빼는전형적인 심방 조동 | Atrial Flutter의 향후 개발 위험 요소미국